Evidence map›Paper›PMID 39375537›Full record

ArticleThe EMBO journal2024

TRPC5 controls the adrenaline-mediated counter regulation of hypoglycemia.

Jenny Bröker-Lai, José Rego Terol, Christin Richter, Ilka Mathar, Angela Wirth, Stefan Kopf, Ana Moreno-Pérez, Michael Büttner, Linette Liqi Tan, Mazen Makke and 30 more

Abstract read
In one paragraph

Article in The EMBO journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. NaThe Journal of membrane biology · 2026
    Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors.

Jenny Bröker-Lai *Institute of Pharmacology, Heidelberg University, Heidelberg, Germany.
José Rego Terol *Center for Integrative Physiology and Molecular Medicine (CIPMM), Saarland University, Homburg, Germany.
Christin Richter *Institute of Pharmacology, Heidelberg University, Heidelberg, Germany.
Ilka Mathar *Institute of Pharmacology, Heidelberg University, Heidelberg, Germany.
Angela Wirth *Institute of Pharmacology, Heidelberg University, Heidelberg, Germany.
Stefan Kopf *Klinik für Endokrinologie, Diabetologie, Stoffwechsel und Klinische Chemie, Heidelberg, Germany.
Ana Moreno-PérezCenter for Integrative Physiology and Molecular Medicine (CIPMM), Saarland University, Homburg, Germany.ORCID http://orcid.org/0009-0000-5465-354X
Michael BüttnerMetabolomics Core Technology Platform, Centre for Organismal Studies Heidelberg (COS Heidelberg), Heidelberg, Germany.
Linette Liqi TanInstitute of Pharmacology, Heidelberg University, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-8684-4698
Mazen MakkeCenter for Integrative Physiology and Molecular Medicine (CIPMM), Saarland University, Homburg, Germany.
Gernot PoschetMetabolomics Core Technology Platform, Centre for Organismal Studies Heidelberg (COS Heidelberg), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-5344-0865
Julia HermannInstitute of Pharmacology, Heidelberg University, Heidelberg, Germany.ORCID http://orcid.org/0009-0001-8545-4698
Volodymyr TsvilovskyyInstitute of Pharmacology, Heidelberg University, Heidelberg, Germany.
Uwe HaberkornNuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Philipp WartenbergExperimental and Clinical Pharmacology and Toxicology, Center for Molecular Signaling (PZMS), Saarland University, Homburg, Germany.
Sebastian SusperreguySignal Transduction Laboratory, Institute of Biomedical Research (BIOMED UCA CONICET) Edificio San José, Piso 3 School of Biomedical Sciences, Pontifical Catholic University of Argentina, Buenos Aires, Argentina.
Michael BerlinInstitute of Pharmacology, Heidelberg University, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-3857-1530
Roger OttenheijmInstitute of Pharmacology, Heidelberg University, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-2137-6173
Koenraad PhilippaertInstitute of Pharmacology, Heidelberg University, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-5861-2275
Moya WuInstitute for Diabetes and Cancer, Helmholtz Diabetes Center, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health (GmbH), 85764, Neuherberg, Germany.
Tobias WiedemannInstitute for Diabetes and Cancer, Helmholtz Diabetes Center, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health (GmbH), 85764, Neuherberg, Germany.ORCID http://orcid.org/0000-0002-8101-7407
Stephan HerzigInstitute for Diabetes and Cancer, Helmholtz Diabetes Center, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health (GmbH), 85764, Neuherberg, Germany.
Anouar BelkacemiInstitute of Pharmacology, Heidelberg University, Heidelberg, Germany.ORCID http://orcid.org/0009-0007-1019-6341
Rebecca T LevinsonDepartment of General Internal Medicine and Psychosomatics, Heidelberg University Hospital, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-2775-7543
Nitin AgarwalInstitute of Pharmacology, Heidelberg University, Heidelberg, Germany.
Juan E Camacho LondoñoInstitute of Pharmacology, Heidelberg University, Heidelberg, Germany.
Bert KleblLead Discovery Center GmbH, Dortmund, Germany.
Klaus DinkelLead Discovery Center GmbH, Dortmund, Germany.
Frank ZufallCenter for Integrative Physiology and Molecular Medicine (CIPMM), Saarland University, Homburg, Germany.ORCID http://orcid.org/0000-0002-4383-8618
Peter NussbaumerLead Discovery Center GmbH, Dortmund, Germany.ORCID http://orcid.org/0000-0002-2761-629X
Ulrich BoehmExperimental and Clinical Pharmacology and Toxicology, Center for Molecular Signaling (PZMS), Saarland University, Homburg, Germany.ORCID http://orcid.org/0000-0003-2436-6907
Rüdiger HellMetabolomics Core Technology Platform, Centre for Organismal Studies Heidelberg (COS Heidelberg), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-6238-4818
Peter NawrothKlinik für Endokrinologie, Diabetologie, Stoffwechsel und Klinische Chemie, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-6134-7804
Lutz BirnbaumerSignal Transduction Laboratory, Institute of Biomedical Research (BIOMED UCA CONICET) Edificio San José, Piso 3 School of Biomedical Sciences, Pontifical Catholic University of Argentina, Buenos Aires, Argentina.
Trese Leinders-ZufallCenter for Integrative Physiology and Molecular Medicine (CIPMM), Saarland University, Homburg, Germany.ORCID http://orcid.org/0000-0002-0678-362X
Rohini KunerInstitute of Pharmacology, Heidelberg University, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-3333-9129
Markus ZornKlinik für Endokrinologie, Diabetologie, Stoffwechsel und Klinische Chemie, Heidelberg, Germany.
Dieter BrunsCenter for Integrative Physiology and Molecular Medicine (CIPMM), Saarland University, Homburg, Germany.
Yvonne SchwarzCenter for Integrative Physiology and Molecular Medicine (CIPMM), Saarland University, Homburg, Germany. Yvonne.Schwarz@uks.eu.
Marc FreichelInstitute of Pharmacology, Heidelberg University, Heidelberg, Germany. Marc.Freichel@pharma.uni-heidelberg.de.ORCID http://orcid.org/0000-0003-1387-2636

Funding

Deutsche Forschungsgemeinschaft (DFG) CRC 894Deutsche Forschungsgemeinschaft (DFG) SFB 1118Deutsche Forschungsgemeinschaft (DFG) SFB 1550Deutsche Forschungsgemeinschaft (DFG) TR-SFB 152Universität des Saarlandes (Saarland University) Young Investigator Grant
6 · The paper itself

Abstract

Hypoglycemia triggers autonomic and endocrine counter-regulatory responses to restore glucose homeostasis, a response that is impaired in patients with diabetes and its long-term complication hypoglycemia-associated autonomic failure (HAAF). We show that insulin-evoked hypoglycemia is severely aggravated in mice lacking the cation channel proteins TRPC1, TRPC4, TRPC5, and TRPC6, which cannot be explained by alterations in glucagon or glucocorticoid action. By using various TRPC compound knockout mouse lines, we pinpointed the failure in sympathetic counter-regulation to the lack of the TRPC5 channel subtype in adrenal chromaffin cells, which prevents proper adrenaline rise in blood plasma. Using electrophysiological analyses, we delineate a previously unknown signaling pathway in which stimulation of PAC1 or muscarinic receptors activates TRPC5 channels in a phospholipase-C-dependent manner to induce sustained adrenaline secretion as a crucial step in the sympathetic counter response to insulin-induced hypoglycemia. By comparing metabolites in the plasma, we identified reduced taurine levels after hypoglycemia induction as a commonality in TRPC5-deficient mice and HAAF patients.

Indexed as

EpinephrineHypoglycemiaMice, KnockoutTRPC Cation ChannelsAnimalsChromaffin CellsFemaleHumansInsulinMaleMiceMice, Inbred C57BLSignal TransductionEpinephrineInsulinTrpc5 protein, mouseTRPC Cation ChannelsAdrenaline SecretionCalcium SignalingChromaffin CellsHypoglycemia Associated Autonomic FailureTRPC5 Channels

Identifiers

PMID39375537
PMCPMC11612138

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.